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Abstract
Background: Epidemiological investigations were carried out following detection of an outbreak of
megaoesophagus in Victorian Police working dogs in early 2018 and an increase in the number of canine
megaoesophagus cases reported by companion animal veterinarians in Eastern Australia starting in late 2017.
VetCompass Australia data were used to quantify the incidence of canine megaoesophagus for the period January
2012 to February 2018 and a matched case-control study carried out to identify individual animal risk factors for
canine megaoesophagus in 2017–2018.
Results: There was a 7-fold increase in the incidence rate of canine megaoesophagus from 2014 (0.11 [95% CI 0.02
to 0.58] cases per 100,000 dogs per day) to 2018 (0.82 [95% CI 0.19 to 4.2] cases per 100,000 dogs per day). Since
2013, the incidence of megaoesophagus in Australia has shown a seasonal pattern, with greater numbers of cases
diagnosed during the warmer months of the year. In the case-control study, use of Mars Petcare Advance
Dermocare as a source of food was 325 (95% CI 64 to 1644) times greater for cases, compared with controls.
Conclusions: Our analyses provide evidence that the feeding of Advance Dermocare was responsible for the
majority of cases in the outbreak of megaoesophagus in Eastern Australia in 2017–2018. The increase in the
incidence rate of megaoesophagus in Australia since 2014–2015 warrants further investigation.
Keywords: Canine megaoesophagus, Epidemiology, Case-control study, Outbreak investigation
Background
Megaoesophagus is a disorder characterised by a hypo-
motile, dilated oesophagus; and may be congenital or ac-
quired, idiopathic or secondary to other disease [1].
Acquired megaoesophagus in dogs is most commonly
idiopathic [2]. Conditions associated with acquired
megaoesophagus include myasthenia gravis, systemic
myopathies, hypoadrenocorticism, lead toxicity, dysauto-
nomia, severe oesophagitis, and systemic lupus erythe-
matosus [3]. Hypothyroidism has been cited as an
underlying cause of acquired secondary megaoesophagus
[4], yet in a case-control study hypothyroidism was not
associated with megaoesophagus [5].
Chronic regurgitation is a characteristic clinical sign of
canine idiopathic megaoesophagus (IMO) and affected
dogs frequently lose body condition and develop aspir-
ation pneumonia [1]. Cervical and thoracic plain and
contrast radiography, including fluoroscopy in non-
anaesthetised patients is used to diagnose megaoesopha-
gus [1]. Further clinical investigations are required to ex-
clude causes of acquired megaoesophagus before a
diagnosis of IMO can be made [1]. Treatment of IMO is
palliative and involves frequent feeding of food in an up-
right position, and medications for associated aspiration
pneumonia (e.g. amoxicillin-clavulonate) and
oesophagitis (e.g. omeprazole) as required [1]. The
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prognosis for IMO in dogs is poor, with owners request-
ing euthanasia because of chronic cachexia and aspir-
ation pneumonia [1].
During late 2017 regurgitation soon after the con-
sumption of food was observed in six dogs owned and
trained by the Victoria (Australia) Police Dog Squad.
From January 2018, this group of dogs were investigated
at the U-Vet Werribee Animal Hospital at the University
of Melbourne. All six dogs were confirmed to have IMO
by radiology, fluoroscopy and additional testing as indi-
cated (e.g. adrenal function testing, endoscopy, electro-
myography and anti-acetylcholine receptor antibody
concentration). After completion of these investigations,
the commercial dry diet routinely fed to Victoria Police
Dog Squad dogs (Advance Dermocare) was hypothesised
to be the most likely causal factor connecting the identi-
fied IMO cases.
Following additional reports of IMO in pet dogs on so-
cial media and to the Australian Veterinary Association,
the commercial dry food diet (Advance Dermocare) was
recalled from the market by its manufacturer, Mars Pet-
care Australia. Subsequently, through notifications by
veterinarians using the PetFAST system (a voluntary
joint initiative of the Australian Veterinary Association
and the Pet Food Industry Association of Australia to
monitor health problems in dogs and cats suspected of
being associated with pet food), communication with
those involved in monitoring the Mar Petcare hotline
and direct communication, further cases were logged
with the University of Melbourne investigators.
To the best of our knowledge, quantitative estimates
of the incidence of IMO in Australia or other countries
have not been reported. We are aware of only one other
outbreak of IMO that occurred in Latvia between 2014
and 2016. In this outbreak, a case-control study showed
that the use of a specific (but different) dry commercial
dog food was more commonly fed to IMO cases, com-
pared with controls (Ilze Matīse, pers. comm., 25 April
2018).
To deal with what appeared to be an emerging disease
problem, an IMO working group was formed in April
2018 comprised of clinicians and veterinary epidemiolo-
gists from the Faculty of Veterinary and Agricultural Sci-
ences at the University of Melbourne. The mandate of
this group was to coordinate activities related to learning
more about the epidemiology of IMO in Australian dogs,
which might then contribute to the development of
evidence-based control strategies. This paper provides a
description of the two main investigatory activities car-
ried out by the IMO working group: (1) provision of es-
timates of the incidence of canine megaoesophagus over
time to provide quantitative evidence that there was an
increase in the frequency of IMO throughout Australia
in 2017–2018, compared with previous years; and (2) a
matched case-control study to identify individual animal
risk factors for IMO.
Results
For the period January 2012 to February 2018 (inclusive)
details of individual veterinary consultations for 1,160,940
dogs were available from VetCompass Australia. Of this
group, 1312 dogs were over 6 months of age and had the
term ‘megaoesophagus’ (or one of its variants) recorded
on at least one occasion in their clinical records.
Figure 1 is a line plot showing the number of cases of
megaoesophagus per 100,000 dogs per day (and its 95%
CI) as a function of calendar time for the period 1 Janu-
ary 2012 to 15 February 2018 (inclusive). Superimposed
on this plot on the secondary vertical axis is a frequency
histogram showing counts of the date of onset of clinical
signs of case-control study IMO cases. There was a 7-
fold increase in the incidence rate of canine megaoeso-
phagus from 2014 to 2018. In 2014 the mean incidence
rate of megaoesophagus was 0.11 (95% CI 0.02 to 0.58)
cases per 100,000 dogs per day; in 2018 the mean inci-
dence rate of megaoesophagus had increased to 0.82
(95% CI 0.19 to 4.2) cases per 100,000 dogs per day.
Since 2013 the incidence of megaoesophagus in
Australia has shown a seasonal pattern, with greater
numbers of cases diagnosed during the warmer months
of the year, as indicated by the upper bounds of the 95%
confidence interval of the IMO incidence rate as a func-
tion of calendar time.
Questionnaires were sent to the owners of 184 pos-
sible IMO cases. Twenty-five questionnaires were subse-
quently removed from the analysis: seven were found
not to be IMO; four cases were not idiopathic (three my-
asthenia gravis and one hypothyroid); two were congeni-
tal megaoesophagus; one presented with atypical signs
putting its diagnosis in doubt; seven had an onset of
clinical signs that was not within the required time
frame for the study; one veterinarian requested that we
send the questionnaire to the referral veterinarian; two
veterinarians requested that the questionnaire be re-
sent; and one was a duplicate. Seventy-seven of the 159
(48%) remaining questionnaires were for dogs that were
subsequently identified as confirmed cases of IMO. A
total of 121 questionnaires were completed for the 237
controls, a response rate of 51%.
Questionnaire details from 77 cases and 121 controls
were available for analysis, a ratio of approximately 1:1.6.
For IMO cases the median date of onset of clinical signs
was 27 January 2018. The range of date of onset of clin-
ical signs was 11 July 2017 to 1 May 2018. Forty-nine
cases (64%) were male (six entire and 43 neutered) and
28 cases (36%) were female (two entire and 26 neutered).
Cases had a median age of 6 years and 8months (IQR
[interquartile range] 4 years 7 months, 8 years 8 months)
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at the time of diagnosis and a median bodyweight of 30
(IQR 25, 39) kg at the time of diagnosis.
Table 1 lists the unconditional associations between
case-control status and each of the putative explanatory
variables with p < 0.20. Breeds over-represented in the
cases included Dalmatians, Golden Retrievers and Labra-
dors and, to a lesser extent, German Shepherds and Ger-
man Shorthaired Pointers. A greater variety of diets were
offered to control dogs compared with case dogs. A
greater proportion of case dogs were fed Mars Petcare Ad-
vance Dermocare compared with control dogs. A smaller
proportion of case dogs were fed canned (wet) commercial
diets, semi-dry commercial diets, scraps or ‘other’ diets
compared with controls. In this study we use the term
‘other diet’ to refer to home-made diets commonly com-
prised of a variety of meats and vegetables. Although data
were collected on manufacturer, brand and the specific
name of all commercial feeds offered, only results for
commercial dry diets are presented in Table 1.
The odds of exposure to a 100% dry food diet, a Mars
dry food diet or a Mars Advance Dermocare diet was
unconditionally greater in cases compared with controls
(p < 0.01, Table 1). The odds of exposure to dry food
brands excluding those specifically assessed in this study
(Purina, Black Hawk, Hill’s and Mars Petcare) and other
Mars Advance brands was unconditionally less in cases
compared with controls (p < 0.01, Table 1).
In the final multivariable model, the odds of routinely
being fed Mars Petcare Advance Dermocare in the 6
months prior to diagnosis was 325 (95% CI 64 to 1644)
times greater for case dogs, compared with control dogs
(Table 2). Five kilogram increases in bodyweight was as-
sociated with a 1.3 (95% CI 1.1 to 1.6) times increase in
the odds of developing IMO (Table 2). The area under
the ROC curve for the predictions from our multivari-
able model was 0.97 indicating that the multivariable
model had excellent ability to discriminate between case
and control dogs.
Fig. 1 Line plot showing the incidence rate of canine megaoesophagus (expressed as the number of cases per 100,000 dogs per day) 1 January
2012 to 15 February 2018. The solid line shows the point estimate of megaoesophagus incidence rate as a function of calendar date. The lower
and upper dashed lines show the lower and upper 95% confidence intervals around the incidence rate estimates. Superimposed on this plot is a
frequency histogram showing date of onset of clinical signs for megaoesophagus cases used in the case-control study
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Fifty-five of the 68 (81%) case dog owners that fed Ad-
vance Dermocare reported that this brand comprised
100% of their dog’s diet. For the remainder of this group,
Advance Dermocare comprised 75% of the diet (n = 13).
A higher proportion of case dogs that were fed 100%
Advance Dermocare were reported as deceased (20 of
55; 36%), compared with those that were fed less than
100% Advance Dermocare (3 of 13, 23%); the uncondi-
tional odds of death for dogs fed 100% Advance Dermo-
care was 1.9 (95% CI 0.47 to 7.7; p = 0.36) times the
odds of being deceased for dogs fed less than 100% Ad-
vance Dermocare. Eleven of the 13 case dog owners who
fed less than 100% Advance Dermocare provided details
on the way it was fed with four mixing it with other
foods, five feeding it separately to other foods and two
using a combination of mixing and separate feeding.
Discussion
Based on the marked increase in the incidence of mega-
oesophagus during late 2017 and early 2018 (Fig. 1), our
inference is that by June 2017 the frequency of megaoe-
sophagus in dogs had increased beyond that expected by
chance and that an outbreak situation did, in fact, exist.
Two features are noteworthy in Fig. 1. Firstly, while the
incidence rate of megaoesophagus was relatively static at
a mean of 0.08 cases per 100,000 dogs per day for the
period January 2012 to 2016, the frequency of disease in-
creased in late 2016 but this increase appears not to
have been sufficient to generate a level of concern
amongst veterinary practitioners to trigger an outbreak
investigation response. Secondly, for the period 2012 to
2018 a seasonal pattern in the incidence rate of megaoe-
sophagus is evident, with greater numbers of cases oc-
curring during the warmer months of each year
Table 1 Risk factors for idiopathic canine megaoesophagus in
Australia, 2017–2018. Unconditional associations between case-
control status and putative explanatory variables with p < 0.20
Variable Number of OR (95% CI) p-value
Cases Controls
Breed:
Labrador 14 7 7.1 (2.4 to 21) < 0.01
Golden Retriever 11 2 19 (3.8 to 99) < 0.01
Dalmatian 9 2 16 (3.0 to 83) < 0.01
German Shepherd 5 3 5.9 (1.2 to 28) 0.02
Other purebred 25 61 1.4 (0.67 to 3.1) 0.34
Crossbreed 13 46 Reference
Gender:
Male 49 61 1.7 (0.94 to 3.0) 0.08
Female 28 59 Reference
Not reported 0 1
Bodyweight (kg):
< 10 2 43 Reference
≥ 10 to 25 21 40 11 (2.5 to 51) < 0.01
≥ 25 to 30 15 13 25 (5.0 to 120) < 0.01
≥ 30 39 18 47 (10 to 210) < 0.01
Not recorded 0 7
Age (years):
< 3 6 29 Reference
≥ 3 to 7 34 41 4.0 (1.5 to 11) < 0.01
≥ 7 to 10 23 15 7.4 (2.5 to 22) < 0.01
≥ 10 8 28 1.4 (0.42 to 4.5) 0.59
Not recorded 6 8
Dry food diet 100%:
Yes 57 22 13 (6.4, 27) < 0.01
No 17 86 Reference
Not recorded 3 13
Purina dry food:
Yes 3 15 0.29 (0.08 to 1.0) 0.04
No 74 106 Reference
Black Hawk dry food:
Yes 0 8 0.09 (0.00 to 1.5) a 0.04
No 77 113 Reference
Mars dry food:
Yes 70 47 16 (6.7 to 37) < 0.01
No 7 74 Reference
Hill’s dry food:
Yes 3 14 0.31 (0.09 to 1.1) 0.06
No 74 107 Reference
‘Other’ dry food: b
Yes 2 21 0.13 (0.03 to 0.56) < 0.01
No 75 100 Reference
Table 1 Risk factors for idiopathic canine megaoesophagus in
Australia, 2017–2018. Unconditional associations between case-
control status and putative explanatory variables with p < 0.20
(Continued)
Variable Number of OR (95% CI) p-value
Cases Controls
Mars Advance Dermocare:
Yes 68 2 450 (94 to 2100) < 0.01
No 9 119 Reference
Mars Advance other:
Yes 1 16 0.09 (0.01 to 0.67) < 0.01
No 76 105 Reference
Mars Royal Canin:
Yes 0 15 0.04 (0.0 to 0.75) a < 0.01
No 77 106 Reference
a Haldane-Anscombe corrected odds ratio
b ‘Other dry food’ means brands of dry food excluding those specifically
assessed in this study (Purina, Black Hawk, Hill’s and Mars Petcare)
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(October to December). We can only speculate regard-
ing the reasons for this finding. Our first possible ex-
planation is that if megaoesophagus was caused by a
toxin present in commercial feed there may be seasonal-
ity in the contamination of commodity feed ingredi-
ent(s). Our second explanation (if there is no seasonal
variation in ingredient contamination) is that the sea-
sonal pattern of megaoesophagus incidence may be due
to increases in the sale, and therefore consumption, of
hypoallergenic canine diets during the warmer months
of the year. A reduction in the incidence of megaoeso-
phagus to less than (say) 0.08 cases per 100,000 dogs per
day following recall of Advance Dermocare from the
Australian market will provide some assurance that con-
tamination was an issue only affecting Advance Dermo-
care whereas an incidence rate of greater than 0.08 cases
per 100,000 dogs per day will provide indirect evidence
that contamination (or otherwise) is an issue affecting
other commercial dog foods, albeit at a lower level than
that experienced by Advanced Dermocare. Samples of
Advance Dermocare were tested by one of the authors
(CM) for minerals and micronutrients (at Massey Uni-
versity, New Zealand), common food toxins, mycotoxins,
neurotoxins and heavy metals (at the National Measure-
ment Institute within the Department of Industry, Sci-
ence, Energy and Resources, Australia and Agrifoods
Australai). Despite testing for an extensive range of pos-
sible toxins, a single agent responsible for the Australian
2017–2018 IMO outbreak has not been identified.1
Comparison of the formulation used for the manufac-
ture of Advanced Dermocare with that used by for the
dog food hypothesised to be the cause of the Latvian
megaoesophagus outbreak [6] and identification of simi-
larities in either the ingredients used or the way they are
processed would provide much needed insight for
identifying the agent responsible for this preventable
cause of debilitating canine illness.
The analyses presented in this paper demonstrate the
enormous value of the VetCompass Australia initiative
as a source of small animal surveillance data. Moving
forward, a challenge for the Australian veterinary profes-
sion and pet food industries is to determine how best to
use VetCompass data to develop proactive approaches
to emerging food-borne disease detection, as opposed to
the entirely reactive approach described in this study.
We identified a strong association between the feeding
of Mars Petcare Advance Dermocare and the develop-
ment of IMO. Dogs that were fed this diet were 325
(95% CI 64 to 1644) times more likely to develop idio-
pathic megaoesophagus compared with dogs fed other
diets. Our unconditional analyses show that dogs fed a
diet comprised of 100% Advance Dermocare was associ-
ated with a greater risk of death from IMO compared
with those dogs where the diet was comprised of less
than 100% Advance Dermocare, providing further sup-
port to the hypothesis that Advance Dermocare was the
cause of this outbreak. Future investigations will docu-
ment the survival of IMO cases arising from the 2017–
2018 Australian outbreak and seek to determine why
only some dogs in multi-dog households were affected,
while others were spared.
Dalmatians, Golden Retrievers and Labradors were
over-represented among cases compared with controls
in this study. These are breeds susceptible to allergic
skin disease [7] and would therefore be expected to be
more likely to have been exposed to Advance Dermocare
or other diets used in the management of allergic skin
disease. Previous research in the United Kingdom deter-
mined the breed distribution of canine megaoesophagus.
Of 71 cases, of which 54 were assessed as idiopathic,
20% were German Shepherds, 8% were Golden Re-
trievers, 8% were Great Danes, 6% were Labradors and
3% were Irish Setters (McBrearty, Ramsey et al. 2011). A
Table 2 Risk factors canine megaoesophagus in Australia, 2017–2018. Estimated regression coefficients and their standard errors
from a mixed-effects logistic regression model of risk factors for idiopathic canine megaoesophagus
Variable Number of Coefficient (SE) p-value OR (95% CI)
Cases Controls
Intercept 77 121 −3.8210 (0.6808) < 0.01
Bodyweight (× 5 kg) 77 121 0.2748 (0.1044) < 0.01 1.3 (1.1 to 1.6)
Advance Dermocare:
Yes 68 2 5.7849 (0.8267) < 0.01 325 (64 to 1644) a
No 9 119 Reference 1.00
Random effect: Variance b
Clinic 0.4652 (1.1498)
a Interpretation: For cases (dogs with IMO) the odds of exposure to Advance Dermocare was 325 (95% CI 64 to 1644) times the odds of exposure to Advance
Dermocare in controls
b Variance of the clinic-level random effect term
1URL: https://www.u-vet.com.au/news/megaesophagus-and-pet-food/
megaoesophagus-and-pet-food-report14122018
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similar distribution of affected breeds (Dobermans and
Bernese Mountain Dogs, but also Labradors, German
Shepherds and Golden Retrievers) was found in the
2016 Latvian outbreak [6]. Differences in the breeds rep-
resented in these studies may be due to breed prefer-
ences in each respective country. The similarities
however suggest that the breed distribution seen in our
study may not be entirely due to the increased chance of
being fed Advance Dermocare but instead may be due
to a breed predisposition to idiopathic canine megaoeso-
phagus. It is also possible that dry food is used preferen-
tially in larger breed dogs due to financial
considerations.
Owners of 64 of the 70 case dogs that were fed Ad-
vance Dermocare reported that they routinely purchased
feed in 15 kg bags; one owner purchased 8 kg bags; three
owners did not provide an answer to this question and
one owner reported buying 3 kg bags initially but then
purchased a large bag after which their dog became ill
approximately 2 weeks later. If only the large size bags
were involved in this outbreak, this supports our finding
that case dogs were heavier than control dogs in the bi-
variate analyses (Table 1). Our logistic regression model
shows that odds of IMO increased by a factor of 1.3
(95% CI 1.1 to 1.6) for 5 kg increases in bodyweight,
after accounting for the effect of feeding Advance Der-
mocare. We conclude from this analysis that dogs that
were of heavier bodyweight were more likely to develop
IMO although the relatively small number of cases for
this study meant that there was insufficient statistical
power to determine if bodyweight was a direct cause of
IMO or if it was confounded by breed.
The media coverage that connected Advance Dermo-
care to IMO cases provided necessary communication
with the dog-owning public and may well have pre-
vented additional cases. Media coverage, however, could
have introduced selection bias into the case-control
study. Public awareness of the suspected cause of the
outbreak could have made it more likely that both
owners and vets of dogs that experienced megaoesopha-
gus and were fed Advance Dermocare diet offered to
participate in the study than those of dogs with megaoe-
sophagus that had not been fed this diet. The investiga-
tors called for any cases of megaoesophagus during the
study period to also be logged, through the Australian
Veterinary Association and a large private veterinary
group, Greencross Vets, in an attempt to address this
potential bias.
As the diagnosis of IMO in dogs is a process of exclu-
sion and not all cases had exhaustive diagnostic
workups, there is the potential for misclassification bias
in outcome status. Since the clinical signs of IMO, in-
volving regurgitation soon after the consumption of food
are characteristic of IMO it is our belief that the impact
of this bias on the inferences made in this study is likely
to be small.
Conclusions
There was a 7-fold increase in the incidence rate of
megaoesophagus in Australia in 2018 compared with
2014. A case-control study to identify risk factors for ca-
nine IMO in Australia between July 2017 and April 2018
found that cases were more likely to have been fed Ad-
vance Dermocare, compared with controls. We conclude
that Advance Dermocare was the cause of this outbreak.
Comparison of the formulation used for the manufac-
ture of Advanced Dermocare with that used by for the
dog food hypothesised to be the cause of the Latvian
megaoesophagus outbreak would provide much needed
insight for identifying the agent responsible for this pre-
ventable cause of debilitating canine illness.
Methods
Two investigations are described in this paper. The first
used data collected by Australian veterinary practices
contributing de-identified individual animal clinical
event data to the VetCompass Australia sentinel practice
surveillance system [8]. The second investigation was a
case-control study designed to identify individual animal
management and feeding practices that rendered dogs
during the period 1 July 2017 to 1 May 2018 at greater
risk of being an incident case of IMO.
Incidence of idiopathic megaoesophagus in Australia,
2012 to 2018
VetCompass Australia collates de-identified electronic
patient record data from primary-care veterinary prac-
tices throughout Australia for epidemiological research
[8]. Veterinary practices that participate in the VetCom-
pass Australia project allow extraction of de-identified
clinical records using appropriately configured practice
management systems. Clinical records extracted by Vet-
Compass include animal demographic details (species,
breed, date of birth, sex, neuter status) as well as free-
text clinical notes recorded by the attending veterinarian
at the time of each consultation. We retrieved two data
extracts from the VetCompass Australia database. The
first comprised clinical records for dogs where the words
‘vomiting’, ‘regurgitation’, and ‘megaoesophagus’ (or
their variants) were included in the animal’s clinical
notes recorded by attending veterinarians at the time of
consultation. The second data extract comprised the
date of birth, the postcode of the owner’s home address
and the month of the last consultation for all dogs listed
in the VetCompass Australia database for the period
January 2012 to February 2018 (inclusive).
We listed the clinical notes for each of the dogs in-
cluded in the first data extract in turn and retrieved the
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animal’s date of birth and the earliest calendar date on
which a consultation occurred where the term ‘megaoe-
sophagus’ (or one of its variants) was recorded. Dogs less
than 6 months of age were not included as these cases
of megaoesophagus were considered more likely to be
congenital. For the second data extract we retrieved the
animal’s date of birth (set to the 15th day of each re-
corded month) and the calendar date of the last veterin-
ary consultation. The two data sets were merged and a
‘status’ variable assigned to each dog, taking the value of
1 for those where the term megaoesophagus were men-
tioned in the clinical records (the first data extract) and
0 otherwise.
The incidence rate of IMO (that is, the number of
IMO positive dogs per 100,000 dogs at risk per day) as a
function of calendar date was estimated using survival
analysis [9]. Here, the outcome of interest was the date
on which IMO was first mentioned in an individual
dog’s clinical notes. Dogs with a status of 0 (described
above) were right censored on the date of their last re-
corded veterinary consultation. The incidence rate of
IMO, interpreted as the probability of a dog being diag-
nosed with IMO per day given that it had remained free
of disease to at least the specified point in time, was
computed using the survival package [10] in R version
3.5.0 [11]. A time series plot was generated showing the
incidence rate of IMO (the number of IMO positive
dogs per 100,000 dogs at risk per day) and its 95% confi-
dence interval as a function of calendar date.
Case-control study
Possible, probable and confirmed cases of IMO for the
case-control study were identified from three sources, as
summarised in Table 3: (1) Mars Petcare; (2) the Pet-
FAST reporting system; and (3) the University of Mel-
bourne. The case definitions provided in Table 4 were
used to distinguish between these groups. Attending vet-
erinarians for each reported case were contacted and re-
quested to complete a web-based questionnaire
developed for the purpose of this study and administered
using REDCap [12]. Clinical details, including an esti-
mate of bodyweight before the onset of clinical signs,
were collected for each reported case as well as details of
exposure to hypothesised risk factors for megaoesopha-
gus such as geographic location, vaccination history, use
of internal and external antiparasitic treatments, housing
and nutritional management (including the amount and
type of feeds typically offered in the 6months before the
onset of clinical signs). Details of other dogs present in
the household at the time of diagnosis were also col-
lected. Possible, probable and confirmed cases of IMO
were defined as ‘cases’ for the case-control study.
Sample size calculations were carried out to determine
the number of control dogs to recruit to determine if
there was a statistically significant association between
routine use of a given named brand of dog food and be-
ing an IMO case. A sample size of 70 case dogs and 70
control dogs was estimated using the Power and Sample
Size Program version 3.0 [13]. These numbers were
based on a case-control ratio of 1:1 with alpha of 0.05
and 80% power to detect an odds ratio (OR) of at least
3.0 for each of the exposures under investigation, assum-
ing the prevalence of exposure amongst the controls was
0.3 and the correlation coefficient for exposure between
matched cases and controls was 0.2.
Risk factors identified during the survey of cases di-
rected the development of the questionnaire for the con-
trols, which was comprised of nine questions regarding
demographic and the use of routine prophylactic treat-
ments plus a series of questions on nutritional manage-
ment. A copy of the questionnaire can be viewed in
Supplementary File 1. The control questionnaire was ad-
ministered using REDCap and used an identical question
format to those used in the case questionnaire. The time
frame of interest for questions that related to nutritional
management was the 6-month period before the date of
presentation to the veterinarian. It was reasoned that
asking questions about how dogs were typically fed over
a relatively short time frame should minimise the impact
of recall bias due to the unavoidable delay between the
timing of the exposures that were being asked about and
administration of the questionnaire.
For controls, veterinarians that had diagnosed a con-
firmed case of IMO were asked to select the three dogs
that had been examined by any veterinarian in the same
practice, immediately prior to the IMO case dog at first
Table 3 Risk factors canine megaoesophagus in Australia, 2017–2018. Details of the different sources of data used to identify
probable cases of megaoesophagus
Source Details
Mars Petcare Database of owners or vets of suspected MO cases shared with University of Melbourne.
Australian Veterinary
Association
PetFAST reports.
University of Melbourne Independent reporting to the U-Vet Werribee Animal Hospital, University of Melbourne from veterinarians and owners, in-
cluding members of a megaoesophagus Facebook community. Reporting to the University of Melbourne responding to
a call for cases sent by Australian Veterinary Association members and by internal communication within the Greencross
Vets group of practices.
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presentation for the condition [14]. If the case dog
was seen too early in the day for this to be possible,
the three dogs examined immediately after the IMO
case were selected as candidate controls. The veterin-
arian that had diagnosed the IMO case was then
asked to contact the owners of each candidate control
dog to ask if they were interested in taking part in
the study. If the owner of a candidate control dog
agreed, the veterinarian either completed the web-
based questionnaire together with the owner or
sought consent from the owner to pass on their con-
tact details to a member of the research team. If the
owner did not agree to take part, the next dog exam-
ined at the clinic was selected as a replacement can-
didate control dog. The questionnaire was
administered by telephone in most instances, but on
some occasions, if the owner preferred, it was con-
ducted by email. For all controls the responses to
each question were transcribed into the questionnaire
database using REDCap.
Data were downloaded from the REDCap database and
statistical analyses carried out using R version 3.5.0 (R Core
Team 2018) using the contributed epiR [15], survival [10]
and R2MLwiN [16] packages. Bivariate (i.e. univariable)
analyses were undertaken to select explanatory variables for
multivariable modelling. The association between categor-
ical exposure variables and dog case-control status was
assessed using the odds ratio, with the Haldane-Anscombe
correction [17, 18] used for comparisons where the fre-
quency of any cell of the 2 × 2 table was equal to zero. The
association between each of the continuously distributed
exposure variables and dog case-control status was assessed
using univariable logistic regression and the association be-
tween each of the categorical explanatory variables and
IMO case status was assessed using the χ2 test. Where vari-
ables were correlated, the most biologically plausible of the
two were selected for further analysis.
Exposure variables associated with a dog having IMO
at an alpha level of less than 0.2 at the bivariate level
were entered into a binary logistic regression model. For
this analysis, the clinic from which case dogs and control
dogs were selected (the matching variable) was included
in the logistic regression model as a random effect term.
A backward elimination process was used to select ex-
planatory variables associated with a dog being an IMO
case. The significance of each explanatory variable in the
model was assessed using the Wald test. Explanatory
variables that were not statistically significant were re-
moved from the model one at a time, beginning with the
least significant, until the estimated regression coeffi-
cients for all the variables retained were significant at an
alpha level of less than 0.05. The results of the final
model are reported in terms of adjusted odds ratios for
each explanatory variable. Assuming a causal relation-
ship between a given exposure and IMO, an adjusted
odds ratio (and its 95% confidence interval) of greater
than 1 indicates that, after adjusting for other variables
in the model, exposure to the explanatory variable in-
creased the odds of a dog being an IMO case. An ad-
justed odds ratio (and its 95% CI) of less than 1
indicates that exposure to the explanatory variable was
protective, and an odds ratio of 1 indicates that the vari-
able was not associated with IMO risk.
A receiver operating characteristic (ROC) curve was
constructed based on the IMO status of dogs predicted
by the model. The area under the ROC curve, which
ranges from zero to one, provided a measure of the
model’s ability to discriminate IMO-positive and IMO-
negative dogs. The greater the area under the ROC
curve the better the model’s discriminatory power.
Use of the VetCompass Australia data for the purpose
described in this study was approved by the University
of Sydney’s Ethics Committee (Project: VetCompass
Australia 2013/919). The case-control questionnaire sur-
vey was approved by the Human Ethics Committee of
the University of Melbourne (Ethics ID 1851740.1). In-
formed verbal consent was obtained from all participants
completing the questionnaire. Verbal, rather than writ-
ten, consent was used because questionnaires were ad-
ministered either by telephone or by electronic mail.
Verbal consent was approved by the Human Ethics
Committee of the University of Melbourne.
Table 4 Risk factors idiopathic canine megaoesophagus in Australia, 2017–2018. Definition of possible, probable and confirmed
cases of idiopathic canine megaoesophagus used in this study
Case
classification
Criteria
Possible A dog with a history of chronic regurgitation ± clinical evidence of aspiration pneumonia.
Probable Evidence of oesophageal dilatation on thoracic radiographs ± evidence of aspiration pneumonia; and
Negative anti-acetylcholine receptor antibody assay.
Confirmed Evidence of oesophageal dilation on thoracic radiographs (without sedation) or fluoroscopic swallowing study ± evidence of
aspiration pneumonia; and
Negative anti-acetylcholine receptor antibody assay; and
Normal baseline cortisol/ACTH stimulation test; and
Normal thyroid function.
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